GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BB Biotech BION.SW · CHF

N/A · SIX · 🇨🇭 Switzerland

Compare

53.50

+3.68%

Close of 9 Nov 2026, in CHF

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About BB Biotech

Its shares trade on SIX under the ticker BION.SW. It has been listed since 8 November 2006. In the fiscal year to 31 December 2025, it reported revenue of CHF 76.8m and net income of CHF 578.1m. At that date it held total assets of CHF 2.79bn and shareholders' equity of CHF 2.78bn.

BB Biotech AG is a CH-based company operating in industry. The company is headquartered in Schaffhausen, Schaffhausen. The company went IPO on 2006-11-08. BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Company’s portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
8 Nov 2006

Leadership

Pay as last reported

  • Dr. Thomas Von PlantaIndependent Chairman of the BoardCHF 376,021
  • Dr. Clive MeanwellIndependent Vice Chairman of the Board, since 2004CHF 280,000
  • Dr. Anna AguadoMember Investment Management Team
  • Dr. Maurizio BernasconiDeputy Head of the Investment Management Team
  • Dr. Can Buldun-GoraMember of the Investment Management Team - Data Scientist
  • Dr. Samuel CrosetMember of the Investment Management Team - Data Scientist
  • Dr. Leonidas GeorgiouMember of the Investment Management Team
  • Dr. Christian KochHead of the Investment Management Team
  • Dr. Wendy LamMember Investment Management Team - Deputy Head and Head of US Research
  • Dr. Olivia WoolleyMember of the Investment Management Team - Data Scientist
  • Ms. Laura HamillIndependent DirectorCHF 260,000
  • Dr. Pearl HuangIndependent DirectorCHF 260,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
58
Environment
71
Social
33
Governance
71
Direct emissions (scope 1)
10 t
Energy emissions (scope 2)
23 t
Value chain emissions (scope 3)
575 t
Carbon reduction policy
Yes
Human rights policy
Yes

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.